{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:14:19Z","timestamp":1780938859349,"version":"3.54.1"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:p>OBJECTIVE. There are few reports in children of overdoses of buprenorphine, a partial opioid agonist used in the treatment of opioid dependence and pain. The purpose of this study was to analyze buprenorphine overdoses in young children reported by US poison centers to the Researched Abuse, Diversion, and Addiction-Related Surveillance System.<\/jats:p><jats:p>METHODS. A retrospective review of buprenorphine overdoses in children &amp;lt;6 years of age reported to the Researched Abuse, Diversion, and Addiction-Related Surveillance System from November 2002 through December 2005 was performed. Patients lost to follow-up and those ingesting multiple substances were excluded.<\/jats:p><jats:p>RESULTS. Eighty-six cases met inclusion criteria. In the 54 children who developed toxicity, the clinical effects included drowsiness or lethargy (55%), vomiting (21%), miosis (21%), respiratory depression (7%), agitation or irritability (5%), pallor (3%), and coma (2%). There were no fatalities. The mean time to onset of effects was 64.2 minutes, with a range of 20 minutes to 3 hours. Duration of clinical effects was under 2 hours in 11%, 2 to 8 hours in 59%, 8 to 24 hours in 26%, and &amp;gt;24 hours in 4%. Children who ingested \u22652 mg of buprenorphine were more likely to experience clinical effects, and all of the children who ingested &amp;gt;4 mg experienced some effect. No child ingesting &amp;lt;4 mg experienced a severe effect. Of the 22 children administered naloxone, 67% had at least a partial response.<\/jats:p><jats:p>CONCLUSIONS. Buprenorphine overdoses are generally well tolerated in children, with significant central nervous system and respiratory depression occurring in only 7%. Any child ingesting &amp;gt;2 mg and children &amp;lt;2 years of age ingesting more than a lick or taste should be referred to the emergency department for a minimum of 6 hours of observation. Naloxone can be used to reverse respiratory depression.<\/jats:p>","DOI":"10.1542\/peds.2007-1774","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T20:25:58Z","timestamp":1207081558000},"page":"e782-e786","source":"Crossref","is-referenced-by-count":53,"title":["Toxicity of Buprenorphine Overdoses in Children"],"prefix":"10.1542","volume":"121","author":[{"given":"Bryan D.","family":"Hayes","sequence":"first","affiliation":[{"name":"Maryland Poison Center, University of Maryland School of Pharmacy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Klein-Schwartz","sequence":"additional","affiliation":[{"name":"Maryland Poison Center, University of Maryland School of Pharmacy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Doyon","sequence":"additional","affiliation":[{"name":"Maryland Poison Center, University of Maryland School of Pharmacy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2021120902143455400_R1","doi-asserted-by":"crossref","unstructured":"Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend.\u20082003;70(2 suppl):S13\u2013S27","DOI":"10.1016\/S0376-8716(03)00056-5"},{"key":"2021120902143455400_R2","unstructured":"Mendelson J, Fernandez E, Welm S, et al. Bioavailability of oral and sublingual buprenorphine and naloxone tablets (abstract PI-113). Clin Pharmacol Ther.\u20082001;69(2):29"},{"key":"2021120902143455400_R3","unstructured":"Suboxone. About suboxone. Available at: www.suboxone.com\/hcp\/suboxone. Accessed June 5, 2007"},{"key":"2021120902143455400_R4","doi-asserted-by":"crossref","unstructured":"Yassen A, Olofsen E, Romberg R, et al. A mechanism-based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther.\u20082007;81(1):50\u201358","DOI":"10.1038\/sj.clpt.6100025"},{"key":"2021120902143455400_R5","doi-asserted-by":"crossref","unstructured":"Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth.\u20082006;96(5):627\u2013632","DOI":"10.1093\/bja\/ael051"},{"key":"2021120902143455400_R6","unstructured":"Food and Drug Administration. Suboxone and subutex official labeling. Available at: www.fda.gov\/cder\/foi\/label\/2002\/20732,20733lbl.pdf. Accessed May 15, 2007"},{"key":"2021120902143455400_R7","doi-asserted-by":"crossref","unstructured":"Yassen A, Olofsen E, Romberg R, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology.\u20082006;104(6):1232\u20131242","DOI":"10.1097\/00000542-200606000-00019"},{"key":"2021120902143455400_R8","doi-asserted-by":"crossref","unstructured":"Geib AJ, Babu K, Ewald MB, Boyer EW. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics.\u20082006;118(4):1746\u20131751","DOI":"10.1542\/peds.2006-0948"},{"key":"2021120902143455400_R9","unstructured":"Researched Abuse, Diversion, and Addiction-Related Surveillance System. Available at: www.radars.org. Accessed May 15, 2007"},{"key":"2021120902143455400_R10","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med.\u20082007;8(2):157\u2013170","DOI":"10.1111\/j.1526-4637.2006.00259.x"},{"key":"2021120902143455400_R11","doi-asserted-by":"crossref","unstructured":"Benson BE, Spyker DA, Troutman WG, Watson WA. TESS-based dose-response using pediatric clonidine exposures. Toxicol Appl Pharmacol.\u20082006;213(2):145\u2013151","DOI":"10.1016\/j.taap.2005.10.009"},{"key":"2021120902143455400_R12","unstructured":"Doyon S, Klein-Schwartz W, Welsh C. Toxicity following buprenorphine ingestions. Clin Toxicol.\u20082005;43(6):640"},{"key":"2021120902143455400_R13","doi-asserted-by":"crossref","unstructured":"Gaulier JM, Charvier F, Monceaux F, Marquet P, Lachatre G. Ingestion of high-dose buprenorphine by a 4 year-old child. J Toxicol Clin Toxicol.\u20082004;42(7):993\u2013995","DOI":"10.1081\/CLT-200042470"},{"key":"2021120902143455400_R14","unstructured":"Spadari M, Arditti J, Affaton MF, David JM, Valli M. Accidental narcotic and buprenorphine poisoning in children notified at the Marseille Poison Center between 1993 and 1999 [in French] [published correction appears in Therapie. 2001;56(1):73]. Therapie.\u20082000;55(6):705\u2013708"},{"key":"2021120902143455400_R15","doi-asserted-by":"crossref","unstructured":"Brewster D, Humphrey MJ, Mcleavy MA. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol.\u20081981;33(8):500\u2013506","DOI":"10.1111\/j.2042-7158.1981.tb13848.x"},{"key":"2021120902143455400_R16","doi-asserted-by":"crossref","unstructured":"Mendelson J, Upton RA, Everhart ET, Jacob P 3rd, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol.\u20081997;37(1):31\u201337","DOI":"10.1177\/009127009703700106"},{"key":"2021120902143455400_R17","doi-asserted-by":"crossref","unstructured":"Kuhlman JJ, Lalani S, Magluilo J, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol.\u20081996;20(6):369\u2013378","DOI":"10.1093\/jat\/20.6.369"},{"key":"2021120902143455400_R18","doi-asserted-by":"crossref","unstructured":"Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther.\u20082001;297(2):688\u2013695","DOI":"10.1016\/S0022-3565(24)29586-0"},{"key":"2021120902143455400_R19","unstructured":"McQuay HJ, Bullingham RE, Bennett MR, Moore RA. Delayed respiratory depression: a case report and a new hypothesis. Acta Anaesthesiol Belg.\u20081979;30(suppl):245S\u2013247S"},{"key":"2021120902143455400_R20","doi-asserted-by":"crossref","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet.\u20081999;37(6):485\u2013505","DOI":"10.2165\/00003088-199937060-00004"},{"key":"2021120902143455400_R21","doi-asserted-by":"crossref","unstructured":"van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology.\u20082006;105(1):51\u201357","DOI":"10.1097\/00000542-200607000-00012"},{"key":"2021120902143455400_R22","unstructured":"Drugs.com. Top 200 drugs for 2006 by sales. Available at: www.drugs.com\/top200.html. Accessed August 10, 2007"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/4\/e782\/1123429\/zpe0040800e782.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/4\/e782\/1123429\/zpe0040800e782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T11:20:19Z","timestamp":1738149619000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/4\/e782\/70908\/Toxicity-of-Buprenorphine-Overdoses-in-Children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1774","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}